9 terminated, 6 completed, 1 suspended, 1 withdrawn. 12 Phase 1, 10 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 12 | Completed 5, Terminated 5, Suspended 1, Withdrawn 1 |
| Phase 2 | 10 | Terminated 7, Completed 1, Suspended 1, Withdrawn 1 |
Follow TPI-287: new trials by email Literature Review of TPI-287 trials Research Report on TPI-287
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Fractionated Stereotactic Radiotherapy (FSRT) in Treatment of Brain Metastases TPI 287, Fractionated Stereotactic Radiotherapy (FSRT) - Brain Metastases, Generalized Malignancy, Primary | Phase 1 | Terminated | H. Lee Moffitt Cancer Center and Research Institute | 15 | 2014-10-09 | 2021-02-04 |
| Safety Study of TPI-287 to Treat CBS and PSP TPI 287 2 mg/m2, TPI-287 20 mg/m2, Placebo - Primary Four Repeat Tauopathies (4RT), Corticobasal Syndrome (CBS) | Phase 1 | Completed | University of California, San Francisco | 44 | 2014-05-01 | 2020-04-15 |
| Safety & Efficacy Study of TPI 287 + Avastin in Adults With Glioblastoma That Progressed Following Prior Avastin Therapy TPI 287, Bevacizumab - Glioblastoma Multiforme | Phase 2 | Terminated | Cortice Biosciences, Inc. | 17 | 2014-01-01 | 2018-01-31 |
| A Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy Study of TPI-287 in Alzheimer's Disease TPI-287 2 mg/m2, TPI-287 6.3 mg/m2, TPI-287 20 mg/m2 - Alzheimer's Disease | Phase 1 | Completed | University of California, San Francisco | 29 | 2013-11-01 | 2020-04-14 |
| Open-Label Study of TPI 287 for Patients With Metastatic Melanoma TPI 287 - Metastatic Melanoma | Phase 1 / Phase 2 | Withdrawn | M.D. Anderson Cancer Center | 2013-09-01 | 2013-04-05 | |
| Dose-Escalation Study of TPI 287 + Avastin Followed by Randomized Study of the Same Versus Avastin for Glioblastoma TPI 287, Bevacizumab - Glioblastoma Multiforme | Phase 1 / Phase 2 | Suspended | Cortice Biosciences, Inc. | 92 | 2013-08-01 | 2023-02-22 |
| Phase I/II Bevacizumab Versus Bevacizumab Plus TPI 287 for Recurrent Glioblastoma TPI287, Bevacizumab - Brain Neoplasms, Central Nervous System Neoplasms | Phase 1 / Phase 2 | Terminated | M.D. Anderson Cancer Center | 12 | 2012-07-01 | 2019-06-05 |
| Safety and Efficacy Study of TPI-287 in Neuroblastoma and Medulloblastoma TPI 287 - Neuroblastoma, Medulloblastoma | Phase 1 / Phase 2 | Terminated | Giselle Sholler | 8 | 2011-12-01 | 2024-08-06 |
| Randomized Efficacy Study of TPI 287 to Treat Primary Refractory or Early Relapsed Neuroblastoma TPI 287, Temozolomide, Irinotecan - Neuroblastoma | Phase 1 / Phase 2 | Terminated | Giselle Sholler | 14 | 2011-12-01 | 2024-08-06 |
| TPI 287 in Breast Cancer Metastatic to the Brain TPI 287, Dexamethasone, Benadryl - Breast Cancer | Phase 2 | Completed | M.D. Anderson Cancer Center | 24 | 2011-08-16 | 2018-09-20 |
| TPI 287 in Patients With Recurrent Glioblastoma Multiforme TPI 287 - Brain Cancer | Phase 2 | Terminated | M.D. Anderson Cancer Center | 17 | 2010-04-01 | 2016-10-31 |
| A Phase I Study of TPI 287 - Temozolomide Combination in Melanoma TPI 287, Temodar (Temozolomide) - Melanoma | Phase 1 | Terminated | M.D. Anderson Cancer Center | 21 | 2010-02-03 | 2017-07-21 |
| TPI 287 in Patients With Refractory or Recurrent Neuroblastoma or Medulloblastoma TPI 287 - Neuroblastoma, Medulloblastoma | Phase 1 | Completed | Giselle Sholler | 18 | 2009-03-01 | 2024-08-06 |
| A Phase II Trial of TPI 287 in Patients Advanced, Unresectable Pancreatic Cancer TPI 287 - Pancreatic Cancer | Phase 2 | Terminated | Cortice Biosciences, Inc. | 23 | 2007-10-01 | 2014-01-22 |
| A Phase II Trial of TPI 287 in Patients With Metastatic Prostate Cancer TPI 287 - Prostate Cancer | Phase 2 | Terminated | Cortice Biosciences, Inc. | 26 | 2007-01-01 | 2014-01-22 |
| Study of TPI 287 Administered Every 21 Days in Patients With Advanced Malignancies TPI 287 Injection - Neoplasms, Hodgkin's Disease | Phase 1 | Completed | Cortice Biosciences, Inc. | 45 | 2005-11-01 | 2007-10-15 |
| Study of TPI 287 in Patients With Advanced Malignancies TPI 287 Injection - Neoplasms, Non-Hodgkin Lymphoma | Phase 1 | Completed | Cortice Biosciences, Inc. | 48 | 2005-05-01 | 2009-06-04 |
Brain Neoplasms (4) · Glioblastoma (4) · Neuroblastoma (3) · Hodgkin Disease (2) · Lymphoma, Non-Hodgkin (2) · Medulloblastoma (2) · Melanoma (2) · Neoplasms (2) · Recurrence (2) · Alzheimer Disease (1) · Breast Neoplasms (1) · Central Nervous System Neoplasms (1) · Color Vision Defects (1) · Corticobasal Degeneration (1) · Disease Progression (1)
Cortice Biosciences, Inc. (6) · M.D. Anderson Cancer Center (5) · Giselle Sholler (3) · University of California, San Francisco (2) · H. Lee Moffitt Cancer Center and Research Institute (1)
United States (17) · Spain (1)
Giselle Sholler, MD (2) · Louis B. Nabors, III, M.D. (2) · Nimish Mohile, M.D. (2) · Pierre Giglio, M.D. (2) · Samuel A. Goldlust, M.D. (2) · Sandra Silberman, MD (2) · Sigmund Hsu, M.D. (2) · Solmaz Sahebjam, M.D. (2) · Tara L. Benkers, M.D. (2) · Adam Boxer, MD, PhD (1) · Adam L Boxer, M.D., Ph.D. (1) · Agop Y. Bedikian, MD, BS (1) · Camilo E. Fadul, M.D., F.A.A.N. (1) · Charles A. Conrad, MD (1) · David Schiff, M.D. (1)